FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.
Carlotta Antoniotti, Marco M Germani, Daniele Rossini...
https://pubmed.ncbi.nlm.nih.gov/35366570Completed
Phase 2
Age: 34Years - 51Years
All Genders
ID00000233
Alternate Day Buprenorphine Administration, Phase X
Led by National Institute on Drug Abuse (NIDA) · Updated on 2005-08-17
N/A
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
N
National Institute on Drug Abuse (NIDA)
Lead Sponsor
U
University of Vermont
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to determine how subjects will make changes in the amount of medication received when given a monetary alternative to buprenorphine.
CONDITIONS
Official Title
Alternate Day Buprenorphine Administration, Phase X - 15
Who Can Participate
Age: 34Years - 51Years
All Genders
Eligibility Criteria
You may qualify if you...
Please contact site for information.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
Trial Site Locations
Total: 1 location
1
Treatment Research Center
Burlington, Vermont, United States, 05401
Status Unknown
Loading map...
How is the study designed?
Study Type
INTERVENTIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
TREATMENT
Number of Arms
0
Similar Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here